You can keep posting this, reaching deep into the bag of hope that the discussion section of a single peer-reviewed report is going to justify widespread adoption of a tech rapidly approaching 3 years in review with its first regulator, and still no submission with the FDA.
You can do that, and continue to ignore critical assessment by people like me, sure. You can also ignore the critical assessment by people not really invested on any level with NWBO (like Vinay Prasad, who you will recall did not have nice things to say about the phase 3 trial).
You can keep trying to wow people here with the copy/paste high-volume commentary. It is not convincing. The longer this goes, the funnier it looks, and the irony of using this Gabagool moniker is pretty funny, given what happened next in that story.